Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Recruiting

Phase 2

Silevertinib & TemozolomideStudy of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Sponsor:

Black Diamond Therapeutics, Inc.

Code:

NCT07326566

Conditions

Glioblastoma (GBM)

Newly Diagnosed Glioblastoma

GBM

Glioblastoma Multiforme (GBM)

Glioma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

silevertinib in combination with temozolomide

temozolomide (TMZ)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-23. This information was provided to ClinicalTrials.gov by Black Diamond Therapeutics, Inc. on 2026-03-19.